Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
December 10, 2024 06:00 ET
|
Cardiff Oncology, Inc.
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control...
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
November 19, 2024 08:00 ET
|
Cardiff Oncology, Inc.
- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq:...
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
November 07, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data...
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
October 30, 2024 16:30 ET
|
Cardiff Oncology, Inc.
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis...
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
August 08, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
May 13, 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
May 02, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated...
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
February 29, 2024 16:07 ET
|
Cardiff Oncology, Inc.
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data...
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
February 29, 2024 16:06 ET
|
Cardiff Oncology, Inc.
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - -...
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
February 29, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the...